A prognostic gene expression signature in infratentorial ependymoma

Khalida Wani, Terri S. Armstrong, Elizabeth Vera-Bolanos, Aditya Raghunathan, David Ellison, Richard Gilbertson, Brian Vaillant, Stewart Goldman, Roger J. Packer, Maryam Fouladi, Ian Pollack, Tom Mikkelsen, Michael Prados, Antonio Omuro, Riccardo Soffietti, Alicia Ledoux, Charmaine Wilson, Lihong Long, Mark R Gilbert, Kenneth D Aldape

Research output: Contribution to journalArticle

90 Citations (Scopus)

Abstract

Patients with ependymoma exhibit a wide range of clinical outcomes that are currently unexplained by clinical or histological factors. Little is known regarding molecular biomarkers that could predict clinical behavior. Since recent data suggest that these tumors display biological characteristics according to their location (cerebral vs. infratentorial vs. spinal cord), rather than explore a broad spectrum of ependymoma, we focused on molecular alterations in ependymomas arising in the infratentorial compartment. Unsupervised clustering of available gene expression microarray data revealed two major subgroups of infratentorial ependymoma. Group 1 tumors over expressed genes that were associated with mesenchyme, Group 2 tumors showed no distinct gene ontologies. To assess the prognostic significance of these gene expression subgroups, real-time reverse transcriptase polymerase chain reaction assays were performed on genes defining the subgroups in a training set. This resulted in a 10-gene prognostic signature. Multivariate analysis showed that the 10-gene signature was an independent predictor of recurrence-free survival after adjusting for clinical factors. Evaluation of an external dataset describing subgroups of infratentorial ependymomas showed concordance of subgroup definition, including validation of the mesenchymal subclass. Importantly, the 10-gene signature was validated as a predictor of recurrence-free survival in this dataset. Taken together, the results indicate a link between clinical outcome and biologically identified subsets of infratentorial ependymoma and offer the potential for prognostic testing to estimate clinical aggressiveness in these tumors.

Original languageEnglish (US)
Pages (from-to)727-738
Number of pages12
JournalActa neuropathologica
Volume123
Issue number5
DOIs
StatePublished - May 1 2012

Fingerprint

Ependymoma
Transcriptome
Genes
Neoplasms
Gene Expression
Recurrence
Gene Ontology
Survival
Mesoderm
Reverse Transcriptase Polymerase Chain Reaction
Cluster Analysis
Real-Time Polymerase Chain Reaction
Spinal Cord
Multivariate Analysis
Biomarkers

Keywords

  • Biomarker
  • Expression profiling
  • Gene expression signature
  • Infratentorial ependymoma
  • Microarray
  • Prognostic genes

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Clinical Neurology
  • Cellular and Molecular Neuroscience

Cite this

Wani, K., Armstrong, T. S., Vera-Bolanos, E., Raghunathan, A., Ellison, D., Gilbertson, R., ... Aldape, K. D. (2012). A prognostic gene expression signature in infratentorial ependymoma. Acta neuropathologica, 123(5), 727-738. https://doi.org/10.1007/s00401-012-0941-4

A prognostic gene expression signature in infratentorial ependymoma. / Wani, Khalida; Armstrong, Terri S.; Vera-Bolanos, Elizabeth; Raghunathan, Aditya; Ellison, David; Gilbertson, Richard; Vaillant, Brian; Goldman, Stewart; Packer, Roger J.; Fouladi, Maryam; Pollack, Ian; Mikkelsen, Tom; Prados, Michael; Omuro, Antonio; Soffietti, Riccardo; Ledoux, Alicia; Wilson, Charmaine; Long, Lihong; Gilbert, Mark R; Aldape, Kenneth D.

In: Acta neuropathologica, Vol. 123, No. 5, 01.05.2012, p. 727-738.

Research output: Contribution to journalArticle

Wani, K, Armstrong, TS, Vera-Bolanos, E, Raghunathan, A, Ellison, D, Gilbertson, R, Vaillant, B, Goldman, S, Packer, RJ, Fouladi, M, Pollack, I, Mikkelsen, T, Prados, M, Omuro, A, Soffietti, R, Ledoux, A, Wilson, C, Long, L, Gilbert, MR & Aldape, KD 2012, 'A prognostic gene expression signature in infratentorial ependymoma', Acta neuropathologica, vol. 123, no. 5, pp. 727-738. https://doi.org/10.1007/s00401-012-0941-4
Wani K, Armstrong TS, Vera-Bolanos E, Raghunathan A, Ellison D, Gilbertson R et al. A prognostic gene expression signature in infratentorial ependymoma. Acta neuropathologica. 2012 May 1;123(5):727-738. https://doi.org/10.1007/s00401-012-0941-4
Wani, Khalida ; Armstrong, Terri S. ; Vera-Bolanos, Elizabeth ; Raghunathan, Aditya ; Ellison, David ; Gilbertson, Richard ; Vaillant, Brian ; Goldman, Stewart ; Packer, Roger J. ; Fouladi, Maryam ; Pollack, Ian ; Mikkelsen, Tom ; Prados, Michael ; Omuro, Antonio ; Soffietti, Riccardo ; Ledoux, Alicia ; Wilson, Charmaine ; Long, Lihong ; Gilbert, Mark R ; Aldape, Kenneth D. / A prognostic gene expression signature in infratentorial ependymoma. In: Acta neuropathologica. 2012 ; Vol. 123, No. 5. pp. 727-738.
@article{419a73015d304e228272af05b19f9d79,
title = "A prognostic gene expression signature in infratentorial ependymoma",
abstract = "Patients with ependymoma exhibit a wide range of clinical outcomes that are currently unexplained by clinical or histological factors. Little is known regarding molecular biomarkers that could predict clinical behavior. Since recent data suggest that these tumors display biological characteristics according to their location (cerebral vs. infratentorial vs. spinal cord), rather than explore a broad spectrum of ependymoma, we focused on molecular alterations in ependymomas arising in the infratentorial compartment. Unsupervised clustering of available gene expression microarray data revealed two major subgroups of infratentorial ependymoma. Group 1 tumors over expressed genes that were associated with mesenchyme, Group 2 tumors showed no distinct gene ontologies. To assess the prognostic significance of these gene expression subgroups, real-time reverse transcriptase polymerase chain reaction assays were performed on genes defining the subgroups in a training set. This resulted in a 10-gene prognostic signature. Multivariate analysis showed that the 10-gene signature was an independent predictor of recurrence-free survival after adjusting for clinical factors. Evaluation of an external dataset describing subgroups of infratentorial ependymomas showed concordance of subgroup definition, including validation of the mesenchymal subclass. Importantly, the 10-gene signature was validated as a predictor of recurrence-free survival in this dataset. Taken together, the results indicate a link between clinical outcome and biologically identified subsets of infratentorial ependymoma and offer the potential for prognostic testing to estimate clinical aggressiveness in these tumors.",
keywords = "Biomarker, Expression profiling, Gene expression signature, Infratentorial ependymoma, Microarray, Prognostic genes",
author = "Khalida Wani and Armstrong, {Terri S.} and Elizabeth Vera-Bolanos and Aditya Raghunathan and David Ellison and Richard Gilbertson and Brian Vaillant and Stewart Goldman and Packer, {Roger J.} and Maryam Fouladi and Ian Pollack and Tom Mikkelsen and Michael Prados and Antonio Omuro and Riccardo Soffietti and Alicia Ledoux and Charmaine Wilson and Lihong Long and Gilbert, {Mark R} and Aldape, {Kenneth D}",
year = "2012",
month = "5",
day = "1",
doi = "10.1007/s00401-012-0941-4",
language = "English (US)",
volume = "123",
pages = "727--738",
journal = "Acta Neuropathologica",
issn = "0001-6322",
publisher = "Springer Verlag",
number = "5",

}

TY - JOUR

T1 - A prognostic gene expression signature in infratentorial ependymoma

AU - Wani, Khalida

AU - Armstrong, Terri S.

AU - Vera-Bolanos, Elizabeth

AU - Raghunathan, Aditya

AU - Ellison, David

AU - Gilbertson, Richard

AU - Vaillant, Brian

AU - Goldman, Stewart

AU - Packer, Roger J.

AU - Fouladi, Maryam

AU - Pollack, Ian

AU - Mikkelsen, Tom

AU - Prados, Michael

AU - Omuro, Antonio

AU - Soffietti, Riccardo

AU - Ledoux, Alicia

AU - Wilson, Charmaine

AU - Long, Lihong

AU - Gilbert, Mark R

AU - Aldape, Kenneth D

PY - 2012/5/1

Y1 - 2012/5/1

N2 - Patients with ependymoma exhibit a wide range of clinical outcomes that are currently unexplained by clinical or histological factors. Little is known regarding molecular biomarkers that could predict clinical behavior. Since recent data suggest that these tumors display biological characteristics according to their location (cerebral vs. infratentorial vs. spinal cord), rather than explore a broad spectrum of ependymoma, we focused on molecular alterations in ependymomas arising in the infratentorial compartment. Unsupervised clustering of available gene expression microarray data revealed two major subgroups of infratentorial ependymoma. Group 1 tumors over expressed genes that were associated with mesenchyme, Group 2 tumors showed no distinct gene ontologies. To assess the prognostic significance of these gene expression subgroups, real-time reverse transcriptase polymerase chain reaction assays were performed on genes defining the subgroups in a training set. This resulted in a 10-gene prognostic signature. Multivariate analysis showed that the 10-gene signature was an independent predictor of recurrence-free survival after adjusting for clinical factors. Evaluation of an external dataset describing subgroups of infratentorial ependymomas showed concordance of subgroup definition, including validation of the mesenchymal subclass. Importantly, the 10-gene signature was validated as a predictor of recurrence-free survival in this dataset. Taken together, the results indicate a link between clinical outcome and biologically identified subsets of infratentorial ependymoma and offer the potential for prognostic testing to estimate clinical aggressiveness in these tumors.

AB - Patients with ependymoma exhibit a wide range of clinical outcomes that are currently unexplained by clinical or histological factors. Little is known regarding molecular biomarkers that could predict clinical behavior. Since recent data suggest that these tumors display biological characteristics according to their location (cerebral vs. infratentorial vs. spinal cord), rather than explore a broad spectrum of ependymoma, we focused on molecular alterations in ependymomas arising in the infratentorial compartment. Unsupervised clustering of available gene expression microarray data revealed two major subgroups of infratentorial ependymoma. Group 1 tumors over expressed genes that were associated with mesenchyme, Group 2 tumors showed no distinct gene ontologies. To assess the prognostic significance of these gene expression subgroups, real-time reverse transcriptase polymerase chain reaction assays were performed on genes defining the subgroups in a training set. This resulted in a 10-gene prognostic signature. Multivariate analysis showed that the 10-gene signature was an independent predictor of recurrence-free survival after adjusting for clinical factors. Evaluation of an external dataset describing subgroups of infratentorial ependymomas showed concordance of subgroup definition, including validation of the mesenchymal subclass. Importantly, the 10-gene signature was validated as a predictor of recurrence-free survival in this dataset. Taken together, the results indicate a link between clinical outcome and biologically identified subsets of infratentorial ependymoma and offer the potential for prognostic testing to estimate clinical aggressiveness in these tumors.

KW - Biomarker

KW - Expression profiling

KW - Gene expression signature

KW - Infratentorial ependymoma

KW - Microarray

KW - Prognostic genes

UR - http://www.scopus.com/inward/record.url?scp=84862644933&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862644933&partnerID=8YFLogxK

U2 - 10.1007/s00401-012-0941-4

DO - 10.1007/s00401-012-0941-4

M3 - Article

C2 - 22322993

AN - SCOPUS:84862644933

VL - 123

SP - 727

EP - 738

JO - Acta Neuropathologica

JF - Acta Neuropathologica

SN - 0001-6322

IS - 5

ER -